Sarah Vogelfanger
Psychiatric/Mental Health · Memphis, TNNPI 1356850283
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,175 of the $93,632 with a category attached, or 82.4%. AbbVie accounts for 89.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $26,790 and has fallen 60.6% since, to $10,545 in 2025. Among psychiatric/mental health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $120.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$84K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$903
- Neurocrine Biosciences, Inc.$781
- plus $5K from 21 others
What the payments were for
- Speaking & faculty fees$77,17582%
- Travel & lodging$2,0392%
- Food & beverage$14,40415%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 287 | $83,676 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 64 | $1,389 |
| Alkermes, Inc. | 52 | $1,264 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,031 |
| Supernus Pharmaceuticals, Inc. | 28 | $903 |
| Neurocrine Biosciences, Inc. | 36 | $781 |
| Axsome Therapeutics, Inc. | 31 | $699 |
| Johnson & Johnson | 31 | $605 |
| Vanda Pharmaceuticals Inc. | 32 | $579 |
| Lundbeck LLC | 31 | $554 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $436 |
| Tris Pharma Inc | 20 | $336 |
| Ironshore Pharmaceuticals Inc. | 12 | $209 |
| E.r. Squibb & Sons, L.L.C. | 3 | $197 |
| Teva Pharmaceuticals USA, Inc. | 12 | $196 |
| Merck | 9 | $154 |
| Collegium Pharmaceutical, Inc. | 9 | $139 |
| Bausch Health US, LLC | 8 | $130 |
| Sunovion Pharmaceuticals Inc. | 7 | $123 |
| Indivior Inc. | 4 | $76 |
| Corium, LLC | 4 | $58 |
| Adlon Therapeutics L.p. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,632 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $258,522 |
| VraylarCariprazine Hcl | 65 | $103,211 |
| Invega SustennaPaliperidone Palmitate | 35 | $92,130 |
| FanaptIloperidone | 27 | $58,990 |
| CaplytaLumateperone Tosylate | 33 | $52,164 |
| RexultiBrexpiprazole | 19 | $26,100 |
| Lurasidone Hcl | 15 | $9,191 |
| Divalproex Sodium ErDivalproex Sodium | 43 | $5,456 |
| Bupropion XlBupropion Hcl | 200 | $4,534 |
| Buspirone Hcl | 214 | $4,398 |
| Duloxetine Hcl | 134 | $4,174 |
| DayvigoLemborexant | 11 | $3,598 |
| Aripiprazole | 102 | $3,136 |
| Olanzapine | 67 | $2,950 |
| Carbamazepine ErCarbamazepine | 22 | $2,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $781 | $258,52229 claims |
| AbbVieVraylar | $83,676 | $103,21165 claims |
| Johnson & JohnsonInvega Sustenna | $605 | $92,13035 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $579 | $58,99027 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,389 | $52,16433 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,031 | $26,10019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Memphis
- Mary AllenMemphis$422K
- Michael HobbsMemphis$23K
- Angela HammondMemphis$16K
- Kristen LockeMemphis$9K
- Latasha GarrettMemphis$8K
- Lisa WilliamsMemphis$8K
- Kristin FitchpatricMemphis$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.